[ad_1]
The COVID-19 vaccine developed by Pfizer and partner biotechnology company BioNTech has been shown to be “very effective” against the coronavirus – including its variants – for at least six months after complete inoculation.
The two companies announced Thursday that the latest phase of testing – which includes an analysis of 927 confirmed symptomatic cases of COVID-19 and 46,307 participants in total – has shown the vaccine to be 91.3% effective against transmission.
In terms of “serious” illness and death, the vaccine is 95% and up to 100% effective, according to definitions established by the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC), respectively. the United States. .
FIRST TRIALS OF MODERNA SOUTH AFRICAN VARIANT COVID-19 VACCINE BEGIN, NIH SAYS
In addition, data from more than 12,000 people who received the Pfizer vaccine demonstrate the safety of the vaccine for a large majority.
“These data confirm the efficacy and favorable safety profile of our vaccine and position us to submit a biologics license application to the US FDA,” said Albert Bourla, chief executive officer of Pfizer, in a statement. . “The high efficacy of the vaccine observed up to six months after a second dose and against the variant prevalent in South Africa increases confidence in the overall efficacy of our vaccine.
CLICK HERE FOR FULL CORONAVIRUS COVERAGE
“This is an important step to further confirm the high efficiency and good safety data that we have seen so far, especially in a longer term follow-up,” added Ugur Sahin, CEO and co-founder of BioNTech. “These data also provide the first clinical results that a vaccine can effectively protect against currently circulating variants, a critical factor in achieving herd immunity and ending this pandemic for the global population.”
Click to learn more about NYPost.com.
[ad_2]
Source link